FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751014734> ?p ?o ?g. }

• W2751014734 endingPage "1166" @default.
• W2751014734 startingPage "1165" @default.
• W2751014734 abstract "We report a case series of 5 patients with quantifiable viral loads at the end of treatment who subsequently achieved sustained virologic response (SVR) with recommended hepatitis C virus (HCV) direct-acting antiviral (DAA) regimens. All 5 patients had HCV genotype 1a, were male, and none were coinfected with human immunodeficiency virus. Their ages ranged from 56 to 67 years. All patients had a baseline viral load between 2,000,000 and 7,000,000 IU/mL (Table 1). Three of the patients received 8 weeks of ledipasvir/sofosbuvir (LDV/SOF), one received 12 weeks of LDV/SOF, and one received 12 weeks of paritaprevir/ritonavir/ombitasvir/dasabuvir with ribavirin (PrOD+RBV). One patient who received 8 weeks of LDV/SOF and the patient who received PrOD+RBV were African American. One of the patients who received LDV/SOF had possible cirrhosis based on his elevated Fibrosis-4 scores; none of the other patients who received LDV/SOF seemed to have cirrhosis. The patient who received PrOD+RBV had compensated cirrhosis. All of the patients who received LDV/SOF were treatment naïve; the patient who received PrOD+RBV had previously received pegylated interferon monotherapy. Two patients receiving LDV/SOF received concomitant omeprazole therapy and were advised to take it at the same time as LDV/SOF. All patients reported complete adherence to the DAA regimen and tolerated treatment well. Viral loads were measured using the Abbott M2000 RealTime System (Abbott Laboratories, Lake Bluff, IL), which has a lower limit of quantification of 12 IU/mL, lower than that in published phase III trials.1Afdhal N. et al.N Engl J Med. 2014; 370: 1889-1898Crossref PubMed Scopus (1431) Google Scholar, 2Kowdley K.V. et al.N Engl J Med. 2014; 370: 1879-1888Crossref PubMed Scopus (989) Google Scholar, 3Feld J.J. et al.N Engl J Med. 2014; 370: 1594-1603Crossref PubMed Scopus (738) Google ScholarTable 1Virologic Trends During and After HCV TreatmentPatientsUnitsBaselineWeek 2Week 4Week 6Week 8Week 10Week 12SVR4SVR121IU/mL2,200,224—35018170——23NDLog_HCV6.34—2.542.261.85——1.36ND2IU/mL2,557,795—496321——<12NDLog_HCV6.41—1.691.801.33——<1.08ND3IU/mL3,852,020—100—51—13NDNDLog_HCV6.59—2—1.71—1.12NDND4IU/mL5,799,6601564486286107——<12NDLog_HCV6.763.192.692.462.03——<1.08ND5IU/mL6467,86930087804412485625<12NDLog_HCV6.813.482.892.642.391.751.40<1.08NDHCV, hepatitis C virus; ND, not detected; SVR, sustained virologic response.End of treatment viral loads are denoted in bold. Open table in a new tab HCV, hepatitis C virus; ND, not detected; SVR, sustained virologic response. End of treatment viral loads are denoted in bold. There are few data on the impact of end of treatment viremia on achieving SVR with DAAs. Sidharthan et al4Sidharthan S. et al.Clin Infect Dis. 2015; 60: 1743-1751Crossref PubMed Scopus (77) Google Scholar assessed the impact of viremia at the end of treatment in predicting SVR. Six patients were identified with quantifiable viremia at end of treatment, five who received 6 weeks of LDV/SOF + GS-9669 and one who received 6 weeks of LDV/SOF + GS-9451. All 6 patients achieved SVR.4Sidharthan S. et al.Clin Infect Dis. 2015; 60: 1743-1751Crossref PubMed Scopus (77) Google Scholar In the ION-2 trial (Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection); 1 patient receiving 12 weeks of LDV/SOF had a viral load of 42 IU/mL at the end of treatment. Subsequent viral loads at weeks 4, 12, and 24 weeks after treatment were undetectable.5Afdhal N. et al.N Engl J Med. 2014; 370: 1483-1493Crossref PubMed Scopus (1163) Google Scholar To our knowledge, there are no additional published accounts describing the impact of quantifiable viral loads at the end of treatment in patients who have received recommended DAA regimens. Sidharthan et al4Sidharthan S. et al.Clin Infect Dis. 2015; 60: 1743-1751Crossref PubMed Scopus (77) Google Scholar offered theories as to the mechanisms of ongoing viral clearance after completion of HCV treatment, namely, the ability of the patient’s innate immune system to eradicate the remaining residual virus after completing therapy. Another theory involves the detection of residual noninfectious viral particles by the HCV assay. A viral kinetic study by McGivern et al6McGivern D.R. et al.Gastroenterology. 2014; 147: 453-462.e7Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar discovered the production of defective virions in the presence of DAAs, detectable by in vitro assays but incapable of assembly and release as infectious virus. The patients in our case series were managed before updated treatment duration recommendations for 8-week LDV/SOF regimens based on subgroup analyses. Backus et al7Backus L.I. et al.Hepatology. 2016; 64: 405-414Crossref PubMed Scopus (155) Google Scholar evaluated the real-world efficacy of LDV/SOF in treatment-naïve Veterans with HCV genotype 1 infections. Independent factors reducing the likelihood of achieving SVR in patients receiving 8 weeks of treatment included those with quantifiable viral loads at week 4 and African Americans. The impact of race is consistent with findings from a study by Su et al,8Su F. et al.Hepatology. 2017; 65: 426-438Crossref PubMed Scopus (60) Google Scholar which evaluated the association between race and treatment failure rates in those receiving either an 8-week or 12-week treatment course of LDV/SOF monotherapy. Although 1 patient in this case series involved an African American man who achieved SVR after 8 weeks of LDV/SOF, the authors do not currently advocate this practice given the currently available literature. Similarly, 2 patients had quantifiable viremia at week 4 of treatment and, thus, should be given a treatment extension to 12 weeks. However, our case series may provide some assurance of SVR if a patient chooses to self-discontinue treatment after only 8 weeks of LDV/SOF. Owing to the limitations of this small case series of 5 patients, definitive conclusions regarding the clinical usefulness of end-of-treatment viral loads cannot be made. Although further studies are needed to determine the significance of quantifiable viremia at the end of treatment, the results of this case series demonstrate that this phenomenon does not always imply therapeutic failure." @default.
• W2751014734 created "2017-09-15" @default.
• W2751014734 creator A5027810401 @default.
• W2751014734 creator A5054413690 @default.
• W2751014734 date "2017-10-01" @default.
• W2751014734 modified "2023-09-26" @default.
• W2751014734 title "Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series" @default.
• W2751014734 cites W2043193067 @default.
• W2751014734 cites W2075335279 @default.
• W2751014734 cites W2081897332 @default.
• W2751014734 cites W2092646281 @default.
• W2751014734 cites W2116998649 @default.
• W2751014734 cites W2151554611 @default.
• W2751014734 cites W2342648336 @default.
• W2751014734 cites W2535010553 @default.
• W2751014734 doi "https://doi.org/10.1053/j.gastro.2017.06.062" @default.
• W2751014734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28881195" @default.
• W2751014734 hasPublicationYear "2017" @default.
• W2751014734 type Work @default.
• W2751014734 sameAs 2751014734 @default.
• W2751014734 citedByCount "4" @default.
• W2751014734 countsByYear W27510147342018 @default.
• W2751014734 countsByYear W27510147342020 @default.
• W2751014734 countsByYear W27510147342023 @default.
• W2751014734 crossrefType "journal-article" @default.
• W2751014734 hasAuthorship W2751014734A5027810401 @default.
• W2751014734 hasAuthorship W2751014734A5054413690 @default.
• W2751014734 hasBestOaLocation W27510147341 @default.
• W2751014734 hasConcept C126322002 @default.
• W2751014734 hasConcept C141071460 @default.
• W2751014734 hasConcept C142462285 @default.
• W2751014734 hasConcept C159047783 @default.
• W2751014734 hasConcept C2522874641 @default.
• W2751014734 hasConcept C2775999097 @default.
• W2751014734 hasConcept C2776408679 @default.
• W2751014734 hasConcept C2776455275 @default.
• W2751014734 hasConcept C2776461080 @default.
• W2751014734 hasConcept C2776979040 @default.
• W2751014734 hasConcept C2777100407 @default.
• W2751014734 hasConcept C2777214474 @default.
• W2751014734 hasConcept C2778390639 @default.
• W2751014734 hasConcept C2778785139 @default.
• W2751014734 hasConcept C2778867932 @default.
• W2751014734 hasConcept C2779298103 @default.
• W2751014734 hasConcept C2780040827 @default.
• W2751014734 hasConcept C2781413609 @default.
• W2751014734 hasConcept C2993143319 @default.
• W2751014734 hasConcept C3013748606 @default.
• W2751014734 hasConcept C71924100 @default.
• W2751014734 hasConcept C90924648 @default.
• W2751014734 hasConceptScore W2751014734C126322002 @default.
• W2751014734 hasConceptScore W2751014734C141071460 @default.
• W2751014734 hasConceptScore W2751014734C142462285 @default.
• W2751014734 hasConceptScore W2751014734C159047783 @default.
• W2751014734 hasConceptScore W2751014734C2522874641 @default.
• W2751014734 hasConceptScore W2751014734C2775999097 @default.
• W2751014734 hasConceptScore W2751014734C2776408679 @default.
• W2751014734 hasConceptScore W2751014734C2776455275 @default.
• W2751014734 hasConceptScore W2751014734C2776461080 @default.
• W2751014734 hasConceptScore W2751014734C2776979040 @default.
• W2751014734 hasConceptScore W2751014734C2777100407 @default.
• W2751014734 hasConceptScore W2751014734C2777214474 @default.
• W2751014734 hasConceptScore W2751014734C2778390639 @default.
• W2751014734 hasConceptScore W2751014734C2778785139 @default.
• W2751014734 hasConceptScore W2751014734C2778867932 @default.
• W2751014734 hasConceptScore W2751014734C2779298103 @default.
• W2751014734 hasConceptScore W2751014734C2780040827 @default.
• W2751014734 hasConceptScore W2751014734C2781413609 @default.
• W2751014734 hasConceptScore W2751014734C2993143319 @default.
• W2751014734 hasConceptScore W2751014734C3013748606 @default.
• W2751014734 hasConceptScore W2751014734C71924100 @default.
• W2751014734 hasConceptScore W2751014734C90924648 @default.
• W2751014734 hasIssue "4" @default.
• W2751014734 hasLocation W27510147341 @default.
• W2751014734 hasLocation W27510147342 @default.
• W2751014734 hasOpenAccess W2751014734 @default.
• W2751014734 hasPrimaryLocation W27510147341 @default.
• W2751014734 hasRelatedWork W2323574296 @default.
• W2751014734 hasRelatedWork W2565807151 @default.
• W2751014734 hasRelatedWork W2587635005 @default.
• W2751014734 hasRelatedWork W2593539364 @default.
• W2751014734 hasRelatedWork W2608524881 @default.
• W2751014734 hasRelatedWork W2618173141 @default.
• W2751014734 hasRelatedWork W2789775952 @default.
• W2751014734 hasRelatedWork W2934391200 @default.
• W2751014734 hasRelatedWork W2945229546 @default.
• W2751014734 hasRelatedWork W2984583494 @default.
• W2751014734 hasVolume "153" @default.
• W2751014734 isParatext "false" @default.
• W2751014734 isRetracted "false" @default.
• W2751014734 magId "2751014734" @default.
• W2751014734 workType "article" @default.